Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 28,805 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Medication Clear all
Enrolling by invitation Not applicable Interventional

Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED

NCT06944353
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Steatosis of Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
STIRRED
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4,704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 25, 2026, 10:31 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)

NCT02856802
View directory record Official record
Conditions
Migraine Headaches
Interventions
Sumatriptan 10 mg Nasal Spray, Sumatriptan Placebo Nasal Spray
Drug · Other
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
San Diego, California • Santa Monica, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 25, 2026, 10:31 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Comparing Inflammatory Markers in Patients With and Without Depression With Chronic Periodontitis

NCT03553095
View directory record Official record
Conditions
Chronic Periodontitis, Depression
Interventions
Periodontal Surgery
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 25, 2026, 10:31 PM EDT
Completed No phase listed Observational

VQI DELTA Paclitaxel Device Safety Analysis

NCT04110288
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Paclitaxel, Non-drug coated Device Treatment
Drug · Device
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
219,483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 25, 2026, 10:31 PM EDT
Terminated Phase 2 Interventional Results available

Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT

NCT00068770
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
radiation therapy, Celecoxib
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 25, 2026, 10:31 PM EDT
Not listed Not applicable Interventional

Safety Action Feedback and Engagement (SAFE) Loop

NCT05381441
View directory record Official record
Conditions
Medication Errors, Patient Safety
Interventions
Safety Action Feedback and Engagement (SAFE) Loop
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Not listed
Enrollment
5,163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 25, 2026, 10:31 PM EDT
Active, not recruiting Not applicable Interventional

DISE: Phenotyping Obstruction Patterns

NCT05050383
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Pharyngeal Manometry
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 10:31 PM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

NCT05819866
View directory record Official record
Conditions
Cerebral Adrenoleukodystrophy (cALD)
Interventions
Leriglitazone, Placebo
Drug
Lead sponsor
Minoryx Therapeutics, S.L.
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Palo Alto, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 25, 2026, 10:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design

NCT04005456
View directory record Official record
Conditions
Health, Subjective, Gastrointestinal Dysfunction, Cardiovascular Risk Factor, Autoimmune Diseases, Dental Diseases, Hormone Disturbance, Neurocognitive Dysfunction
Interventions
Supplements and/or medical foods, Behavioral change support program, Food plan
Dietary Supplement · Behavioral · Other
Lead sponsor
Metagenics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Gig Harbor, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 25, 2026, 10:31 PM EDT
Completed Not applicable Interventional

Using the Telephone to Improve Care in Childhood Asthma

NCT00660322
View directory record Official record
Conditions
Asthma
Interventions
Telephone Asthma Program
Behavioral
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
5 Years to 12 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 17, 2008 · Synced Oct 25, 2026, 10:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children

NCT02991937
View directory record Official record
Conditions
Appendicitis
Interventions
Piperacillin/Tazobactam, Surgical Treatment
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 25, 2026, 10:31 PM EDT
Terminated Not applicable Interventional Results available

Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia

NCT01230788
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia, ALL
Interventions
rituximab
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Atlanta, Georgia • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Oct 25, 2026, 10:31 PM EDT
Active, not recruiting Phase 2 Interventional

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT03844061
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 10:31 PM EDT
Recruiting Phase 2 Interventional

Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients

NCT04721873
View directory record Official record
Conditions
Colitis, Ulcerative, Obesity
Interventions
Phentermine-Topiramate, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 25, 2026, 10:31 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

NCT04060173
View directory record Official record
Conditions
Hyperuricemia, Gout
Interventions
ABP-671, Placebo
Drug · Other
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 25, 2026, 10:31 PM EDT
Not listed Phase 2 Interventional

Hormone Replacement Therapy and Insulin Action: A Double-Blind, Parallel, Placebo-Controlled Hormone Intervention Study in Postmenopausal Women

NCT00005769
View directory record Official record
Conditions
Menopause
Interventions
Hormone Replacement Therapy
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
45 Years to 55 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 10:31 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma

NCT04165941
View directory record Official record
Conditions
Brain Tumor Adult
Interventions
DRI cell therapy
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 25, 2026, 10:31 PM EDT
Terminated Phase 3 Interventional Results available

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

NCT02377466
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban IV infusion, Placebo IV infusion
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
33
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 25, 2026, 10:31 PM EDT
Completed Phase 1 Interventional

Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

NCT00006066
View directory record Official record
Conditions
HIV Infections
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Diphtheria and Tetanus Toxoids Adsorbed, Tetanus and Diphtheria Toxoids Adsorbed, Bacteriophage phi X 174, Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 25, 2026, 10:31 PM EDT
Not listed Phase 1 Interventional

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

NCT05487651
View directory record Official record
Conditions
NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma, ALL, Adult B Cell, ALL, Childhood, CLL/SLL
Interventions
KUR-502
Genetic
Lead sponsor
Athenex, Inc.
Industry
Eligibility
3 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Francisco, California • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 25, 2026, 10:31 PM EDT
Withdrawn Phase 3 Interventional

A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug

NCT03108729
View directory record Official record
Conditions
Epilepsy
Interventions
Eslicarbazepine acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
4 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Henderson, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 25, 2026, 10:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium

NCT02831231
View directory record Official record
Conditions
Schizophrenia
Interventions
xanomeline tartrate, Trospium chloride
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 25, 2026, 10:31 PM EDT
Completed Phase 2 Interventional

Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab

NCT03126331
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 25, 2026, 10:31 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

NCT03811002
View directory record Official record
Conditions
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Etoposide, Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
532
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 400 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 25, 2026, 10:31 PM EDT